# Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen

> **NCT04346615** · PHASE2,PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 47 (actual)

## Conditions studied

- COVID-19 Infection

## Interventions

- **DRUG:** Zavegepant (BHV-3500)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04346615
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-25
- **Primary completion:** 2022-04-29
- **Final completion:** 2022-04-29
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Lack of enrollment due to evolution of COVID-19 pandemic with reduction in patients at risk for severe disease and growing number of effective alternative therapies
- **Last updated:** 2024-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04346615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04346615, "Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04346615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*